446 related articles for article (PubMed ID: 25395392)
1. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
Pisani A; Riccio E; Sabbatini M; Andreucci M; Del Rio A; Visciano B
Nephrol Dial Transplant; 2015 Apr; 30(4):645-52. PubMed ID: 25395392
[TBL] [Abstract][Full Text] [Related]
2. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.
Macdougall IC; Bock A; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Cushway T; Roger SD;
Nephrol Dial Transplant; 2014 Apr; 29(4):843-50. PubMed ID: 24170814
[TBL] [Abstract][Full Text] [Related]
3. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Oral Supplementation with Liposomal Iron in Non-Dialysis Chronic Kidney Disease Patients with Iron Deficiency.
Cesarano D; Borrelli S; Campilongo G; D'Ambra A; Papadia F; Garofalo C; De Marco A; Marzano F; Ruotolo C; Gesualdo L; Cirillo P; Minutolo R
Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732502
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
[TBL] [Abstract][Full Text] [Related]
6. Liposomal iron in moderate chronic kidney disease.
Montagud-Marrahi E; Arrizabalaga P; Abellana R; Poch E
Nefrologia (Engl Ed); 2020; 40(4):446-452. PubMed ID: 31892487
[TBL] [Abstract][Full Text] [Related]
7. Heme iron polypeptide for the management of anaemia of chronic kidney disease.
Dull RB; Davis E
J Clin Pharm Ther; 2015 Aug; 40(4):386-90. PubMed ID: 25953602
[TBL] [Abstract][Full Text] [Related]
8. [Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice].
Rottembourg J; Rostoker G
Nephrol Ther; 2015 Dec; 11(7):531-42. PubMed ID: 26498106
[TBL] [Abstract][Full Text] [Related]
9. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A
Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965
[TBL] [Abstract][Full Text] [Related]
11. Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.
Riccio E; Sabbatini M; Capuano I; Pellegrino AM; Petruzzelli LA; Pisani A
BMC Nephrol; 2020 Feb; 21(1):57. PubMed ID: 32087684
[TBL] [Abstract][Full Text] [Related]
12. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
[TBL] [Abstract][Full Text] [Related]
13. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis.
Rozen-Zvi B; Gafter-Gvili A; Paul M; Leibovici L; Shpilberg O; Gafter U
Am J Kidney Dis; 2008 Nov; 52(5):897-906. PubMed ID: 18845368
[TBL] [Abstract][Full Text] [Related]
14. Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial.
Nagaraju SP; Cohn A; Akbari A; Davis JL; Zimmerman DL
BMC Nephrol; 2013 Mar; 14():64. PubMed ID: 23514036
[TBL] [Abstract][Full Text] [Related]
15. Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.
Gaillard CA; Bock AH; Carrera F; Eckardt KU; Van Wyck DB; Bansal SS; Cronin M; Meier Y; Larroque S; Roger SD; Macdougall IC
PLoS One; 2016; 11(6):e0157063. PubMed ID: 27276035
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
17. Iron therapy for managing anaemia in chronic kidney disease.
Macdougall IC
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):358-363. PubMed ID: 29905580
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL; Morris D; Warady BA
Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD.
Van Wyck DB; Roppolo M; Martinez CO; Mazey RM; McMurray S;
Kidney Int; 2005 Dec; 68(6):2846-56. PubMed ID: 16316362
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
